p53 and MDM2 alterations in osteosarcomas: Correlation with clinicopathologic features and proliferative rate

Cancer

Volumn 79, Issue 8, 1997, Pages 1541-1547

  Lonardo, Fulvio ^a   Ueda, Takafumi ^a,b   Huvos, Andrew G ^a   Healey, John ^a   Ladanyi, Marc ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Osaka Medical Center for Cancer   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; ARTICLE; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; PAGET BONE DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; TUMOR GROWTH;

ADULT; BLOTTING, SOUTHERN; BONE NEOPLASMS; CELL DIVISION; GENE AMPLIFICATION; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; NUCLEAR PROTEINS; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 0030964879     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1541::AID-CNCR15>3.0.CO;2-Y     Document Type: Article

References (53)

1. Levine AJ. The p53 tumor-suppressor gene. N Engl J Med 1992;326:1350-1.
2. Porter PL, Gown AM, Kramp SG, Coltrera MD. Widespread p53 overexpression in human malignant tumors. Am J Pathol 1992;140:1453.
3. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal development. N Engl J Med 1988;319:525-32.
4. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 1992;356:215-21.
5. Lavigueur A, Maltby V, Mock D, Rossant J, Pawson T, Bernstein A. High incidence of lung, bone and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 1989;9:3982-91.
6. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild type p53. Science 1990;249:912-15.
7. Metz T, Harris AW, Adams JM. Absence of p53 allows direct immortalization of hemopoietic cells by the myc and raf oncogenes. Cell 1995;82:29-36.
8. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin 6. Nature 1991;352:345-47.
9. Lowe SW, Ruley EH, Jacks T, Housman DE. P53 dependent apoptosis modulates the cytotoxicity of anticancer drugs. Cell 1993;74:957-67.
10. Lowe SW, Schmidt EM, Smith SW, Osborne BA, Jacks T. P53 is required for radiation induced apoptosis in mouse thymocytes. Nature 1993;362:847-849.
11. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
12. Miller CW, Abdulkarim A, Tsay C, Slamon D, Ishizaki K, Toguchida J, et al. Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res 1990;50:7950-4.
13. Toguchida J, Yagamuchi T, Ritchie B, Beauchamp RL, Dayton SH, Herrera GE, et al. Mutation spectrum of the p53 gene in bone and soft tissue sarcoma. Cancer Res 1992;52:6194-9.
14. Ueda Y, Dockhorn-Dworniczack B, Blasius S, Mellin W, Wuisman P, Bocker W, et al. Analysis of mutant p53 protein in osteosarcomas and other malignant and benign lesions of bone. J Cancer Res Clin Oncol 1993;119:172-8.
15. Wadayama B, Toguchida J, Yamaguchi T, Sasaki MS, Yamamuro T. p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br J Cancer 1993;68:1134-9.
16. Mousses S, McAuley L, Bell RS, Kandel R, Andrulis IL. Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas. Mod Pathol 1996;9:1-6.
17. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
18. Momand J, Zambetti GP, Olson DC, George DL, Levine AJ. The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell 1992;69:1237-45.
19. Xiao ZX, Chen J, Levine A, Modjtahedi N, Xing J, Sellers WR, et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995;375:694-8.
20. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-3.
21. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, et al. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993;53:2231-4.
22. Habuchi T, Kinoshita H, Yamada H, Kakehi Y, Ogawa O, Wu WJ et al. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J Natl Cancer Inst 1994;86:1331-5.
23. Lianes P, Orlow I, Zhang ZF, Oliva MR, Sarkis AS, Reuter VE, et al. Altered patterns of MDM2 and P53 expression in human bladder cancer. J Natl Cancer Inst 1994;86:1325-30.
24. Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54:794-9.
25. Nakayama T, Toguchida J, Wadayama B, Kanoe H, Kotoura Y, Sasaki MS. MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose tissue tumors. Int J Cancer 1996;64:342-6.
26. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 1993;53:16-8.
27. Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ, Look AT. Coamplification of the CDK4 gene with MDM2 and Gli in human sarcomas. Cancer Res 1993;53:5535-41.
28. Vogelstein B, Kinzler K. P53 function and dysfunction. Cell 1992;7:523-6.
29. Florenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, Fodstadt O. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst 1994;86:1297-302.
30. Fechner RE, Mills SE. Tumors of the bones and joints. In: Rosai J, Sobin LH, editors. Atlas of tumor pathology. 3rd Series. Fascicle 8. Washington DC: Armed Forces Institute of Pathology, 1993:39.
31. Baas IO, Mulder JR, Offerhaus GJA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
32. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine J. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-9.
33. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-5.
34. Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin fixed paraffin sections. J Pathol 1992;168:357-63.
35. Hinds PW, Finlay CA, Quartin RS, Baker SJ, Fearon ER, Vogelstein B, et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotype. Cell Growth Differ 1990;1:571-80.
36. Hall PA, Lane D. P53 in tumor pathology: can we trust immunohistochemistry? Revisited! J Pathol 1994;172:1-4.
37. Miller CW, Aslo A, Won A, Tan M, Lampkin B, Koeffler P. Alterations of the p53, Rb and MDM2 gene in osteosarcomas. J Cancer Res Clin Oncol 1996;122:559-65.
38. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991;10:1565-9.
39. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nature Med 1996;2:912-7.
40. Keleti J, Quezado MM, Abaza MM, Raffeld M, Tsokos M. The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Am J Pathol 1996;149:143-51.
41. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992;70:923-35.
42. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992;70:937-48.
43. Ladanyl M, Lewis R, Jhanwar SC, Gerald W, Huvos AG, Healey JH. MDM2 and CDK4 gene amplification in Ewing's sarcoma. J Pathol 1995;175:211-7.
44. Noble-Topham SE, Burrow SR, Eppert K, Kandel RA, Meltzer PS, Bell RS, et al. SAS is amplified predominantly in surface osteosarcoma. J Orthop Res 1996;14:700-5.
45. Drobnjak M, Latres E, Pollack D, Karpeh M, Dudas M, Woodruff JM, et al. Prognostic implications of p53 nuclear overexpression and high proliferative index of Ki-67 in adult soft tissue sarcoma. J Natl Cancer lnst 1994;86:549-54.
46. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary-node negative breast cancer. N Engl J Med 1992;326:1756-61.
47. Gelsleichter L, Gown AM, Zarbo RJ, Wang E, Coltrera MD. P53 and mdm2 expression in malignant melanoma: an immunohistochemical study of expression of p53, mdm2 and markers of cell proliferation in primary versus metastatic tumors. Mod Pathol 1995;8:530-5.
48. Beck T, Weller EE, Weikel W, Brumm C, Wilkens C, Knapstein PG. Usefulness of immunohistochemical stain for p53 in the prognosis of breast carcinomas: correlation with established prognosis parameters and with the proliferative marker Mib-1. Gynecol Oncol 1995;57:96-104.
49. Isola J, Visakorpi T, Holli K, Kallioniemi OP. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992;84:1009-14.
50. Craig Allred D, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-6.
51. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, et al. P53 as an independent prognostic marker in lymph node-negative breast cancer patients. Natl Cancer Inst 1993;85:965-70.
52. Moch H, Sauter G, Mihatsch MJ, Gudat F, Epper R, Waldman FM. P53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer. Hum Pathol 1994;25:1346-51.
53. Nylander K, Stenling R, Gustaffson H, Zackrisson B, Roos G. P53 expression and cell proliferation in squamous cell carcinomas of the head and neck. Cancer 1995;75:87-93.